- Product NameXL184(Cabozantinib malate)
- Brief DescriptionInhibitors
- Purification100.00%
- Biological ActivityCabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of Y cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.
- Target Namec-Kit inhibitor; c-Met/HGFR inhibitor; TAM Receptor inhibitor; VEGFR inhibitor
- CAS No. 1140909-48-3
- Calculated MW 635.59
- Formulation C32H30FN3O10
- Storage 3 years -20˚C powder;2 years -80˚C in solvent;
